132 related articles for article (PubMed ID: 11389126)
1. Conventional dogma applied to quinolones? Time for a change.
Jones RN
J Antimicrob Chemother; 2001 Jun; 47(6):893. PubMed ID: 11389126
[No Abstract] [Full Text] [Related]
2. [Pneumococcus and quinolone resistance].
Bello S; Torres A
Arch Bronconeumol; 2003 Mar; 39(3):97-100. PubMed ID: 12622966
[No Abstract] [Full Text] [Related]
3. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
4. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
Johnson AP; Warner M; George RC; Livermore DM
J Antimicrob Chemother; 2001 Apr; 47(4):411-5. PubMed ID: 11266412
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
Schentag JJ
J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
[TBL] [Abstract][Full Text] [Related]
6. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG
J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Boswell FJ; Andrews JM; Wise R
J Antimicrob Chemother; 2001 Sep; 48(3):446-7. PubMed ID: 11533016
[No Abstract] [Full Text] [Related]
8. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin in the therapy of experimental pneumococcal meningitis.
Schmidt H; Dalhoff A; Stuertz K; Trostdorf F; Chen V; Schneider O; Kohlsdorfer C; Brück W; Nau R
Antimicrob Agents Chemother; 1998 Jun; 42(6):1397-407. PubMed ID: 9624483
[TBL] [Abstract][Full Text] [Related]
10. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Rubinstein E; Diamantstein L; Yoseph G; Gruzman G; Rubinovitch B; Barzilai A; Keller N
Clin Microbiol Infect; 2000 Dec; 6(12):678-81. PubMed ID: 11284929
[No Abstract] [Full Text] [Related]
11. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
12. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Pestova E; Millichap JJ; Noskin GA; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
[TBL] [Abstract][Full Text] [Related]
13. Quinolones and pneumococci.
Tillotson GS; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):709-10. PubMed ID: 10797099
[No Abstract] [Full Text] [Related]
14. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
15. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
[TBL] [Abstract][Full Text] [Related]
16. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
Dalhoff A; Krasemann C; Wegener S; Tillotson G
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
[TBL] [Abstract][Full Text] [Related]
17. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
18. In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
Rodríguez JC; Llinares F; Royo G
Chemotherapy; 2001; 47(1):39-42. PubMed ID: 11125231
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
Etienne M; Croisier D; Charles PE; Lequeu C; Piroth L; Portier H; Drlica K; Chavanet P
J Infect Dis; 2004 Oct; 190(8):1472-5. PubMed ID: 15378440
[TBL] [Abstract][Full Text] [Related]
20. Gatifloxacin and moxifloxacin: two new fluoroquinolones.
Med Lett Drugs Ther; 2000 Feb; 42(1072):15-7. PubMed ID: 10705891
[No Abstract] [Full Text] [Related]
[Next] [New Search]
